SynthesisBMC nephrology2026
Efficacy and safety of low-dose combination urate-lowering agent therapy versus standard-dose monotherapy in patients with hyperuricemia and/or gout: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment to lower uric acid levels is usually administered using monotherapy. However, this may be insufficiently effective for all patients. We hypothesized that a low-dose combination of drugs with different mechanisms of action might be more effective than standard-dose monotherapy. To test this theory, we conducted a systematic review and meta-analysis.
methodWe searched MEDLINE and the Cochrane Library to identify randomized controlled trials that compared combination therapy involving low-dose urate-lowering drugs with standard-dose monotherapy. The primary outcome was serum uric acid levels at the end of treatment, and the data were analyzed using a random-effects model. Adverse events were assessed qualitatively.
resultsThis review included four trials involving 342 participants. Statistically significant reductions in serum uric acid levels were observed with low-dose combination therapy compared to monotherapy (mean difference: -0.47 mg/dL; 95% confidence interval: -0.68 to -0.26). No statistically significant heterogeneity was observed (I² = 0.0%). No serious adverse events were reported in either group.
conclusionsThe results suggest that low-dose combination therapy with urate production inhibitors and urate excretion promoters may be more effective at lowering serum uric acid levels compared with standard-dose monotherapy. However, as the assessment of adverse events was qualitative and the certainty of the safety evidence was extremely low, it remains unclear whether there are differences in the safety profiles between treatment strategies. Further randomized controlled trials are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.